Aaron Gerds, MD

Aaron Gerds, MD, is an assistant professor of Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute in Ohio.

Articles

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Dr Gerds on the Development of Anemia in Low-Risk Myelofibrosis

May 7th 2025

Aaron Gerds, MD, details the prevalence of anemia in patients with low- to intermediate-1–risk myelofibrosis.

Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results From the ACE-536-MF-001 Study

April 16th 2025

Dr. Aaron Gerds presents results from the Phase 2 ACE-536-MF-001 study, demonstrating that luspatercept improves anemia in patients with myelofibrosis—with or without transfusion dependence—and shows encouraging activity when combined with ruxolitinib, with a manageable safety profile and no new safety signals.

Dr Gerds on Efficacy Data Supporting the Use of Momelotinib in Myelofibrosis With Anemia

December 17th 2024

Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

October 14th 2024

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

August 6th 2024

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

Dr Gerds on Disease Progression Patterns in Low-Risk Myelofibrosis

July 10th 2024

Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis.

Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

June 14th 2024

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

May 31st 2024

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor–Naive Myelofibrosis

January 4th 2024

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Looking Ahead in Treating Myeloproliferative Neoplasms

April 26th 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

April 26th 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Novel Therapies Under Investigation for Myelofibrosis

April 19th 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Treatment Sequencing Approaches for Myelofibrosis

April 19th 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Monitoring Strategies in Myelofibrosis

April 12th 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

JAK Inhibitors in Myelofibrosis

April 12th 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Transplant Therapy in Myelofibrosis

April 5th 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.